<DOC>
	<DOCNO>NCT02807025</DOCNO>
	<brief_summary>Nasal , tracheal bronchial sample MLF patient idiopathic pulmonary fibrosis ( IPF ) , sarcoidosis , tuberculosis ( TB ) , asthma COPD . Similar sample healthy control comparative data . Aim : To characterise molecular basis upper low airway mucosa inflammatory response different respiratory disease . To assess molecular biomarkers signature see aid diagnosis , stratification respiratory disease . To direct personalised medicine rationalise therapy . Outcome measure : Measurement level inflammation , coagulation , complement activation fibrosis MLF , transcriptomics nasal curettage airway brush assess tolerability absorption procedures patient .</brief_summary>
	<brief_title>Nasal , Tracheal Bronchial Mucosal Lining Fluid ( MLF ) Sampling From Patients With Respiratory Diseases</brief_title>
	<detailed_description>Aim- To define diagnosis , stratification monitoring IPF , sarcoidosis TB , provide target biomarkers new therapy . The investigator study asthma COPD patient inflammation airway , compare healthy control subject . Characterising inflammation use upper airway sample may eventually remove requirement invasive diagnostic bronchoscopy patient . The investigator shall assess presence cytokine , chemokines , together complement , coagulation fibrosis . The investigator propose obtain opportunistic nasal , bronchial tracheal mucosal sample patient IPF , sarcoidosis TB . The investigator compare sample healthy control patient asthma COPD . Objectives : Determining biomarkers molecular signature term cytokine chemokines , coagulation , complement activation fibrosis MLF range lung disease Study design : This pilot study investigator shall obtain study group patient attend bronchoscopy suite , specialist respiratory clinic admit ward St Mary 's Hospital Respiratory team . The investigator shall recruit patient asthma COPD , well age/ sex- match healthy volunteer . IPF , sarcoid TB patient usually undergo bronchoscopy endobronchial ultrasound ( EBUS ) transbronchial needle aspiration ( TBNA ) diagnostic purpose . Their diagnosis may confirm sample do bronchoscopy . The patient include study represent follow group : IPF least 12 subject Sarcoidosis least 12 subject TB least 12 subject COPD least 12 subject Asthma least 12 subject Healthy least 12 subject Study visit : Having identify patient suitable study , study involve single bronchoscopy , airway sample take place . The investigator recruit patient asthma , COPD healthy volunteer reimburse participation , since bronchoscopy routinely part normal clinical care . They recruit advertisement general public . They give relevant participant information sheet regard study email post . Participants confirm suspected IPF , sarcoidosis TB due bronchoscopy identify routine clinical care part diagnostic work-up , receive compensation .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Respiration Disorders</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<criteria>Inclusion criterion participant Women childbearing age pregnant , plan get pregnant breastfeeding . Participants upper respiratory tract infection past 6 week . Participants significant cardiovascular disease . Body mass index ( BMI ) 18 39 . Participants sign symptom significant nasal anatomical defect include hypertrophy turbinate , major septum deviation , nasal polyposis recurrent sinusitis nasal mucosal defect , injury , ulceration undergo nasal sample . All participant able provide inform consent . Healthy volunteer history lung disease , age 1865 , BMI 1839 , PEF &gt; 90 % , reversibility , atopy , non smoker/ ex smoker &gt; 10PYH . Asthma diagnosis asthma , age 1865 , BMI 1839 , GINA mild , PEF &gt; 70 % , reversibility salbutamol positive histamine , well control asthma questionnaire ( ACQ &lt; 0.75 ) , non smoker/ex smoker &lt; 10PYH . IPF HRCT suggestive ofILD/IPF , age 4580 , BMI 1839 , FVC &gt; 50 % , DLCO 3090 % . Sarcoidosis HRCT suggestive sarcoidosis , age 1895 , BMI 1839 , FVC &gt; 50 % , DLC0 &gt; 30 % . TB sarcoidosis , include clinical history and/ CT evidence TB , age 1865 . COPD diagnosis COPD , age 4565 , age 1839 , gold stage 2 , post bronchodilator FEV1 5079 % , FEV1/FVC ratio &lt; 70 % , TLCO 6080 % emphysema HRCT , Smoker/ex smoker &gt; 10PYH . Healthy volunteer use antiinflammatory med include statin , antihistamine , NSAIDs , salicylates , antirheumatics , use OTC medication , URTI within last six week , chronic inflammatory illness CVS/ Resp disease/ systemic disease . Asthma Use inhale corticosteroid last 4 week , use oral steroid last 6 month , use anti inflammatory med include statin , antihistamine , NSAIDs , salicylates , antirheumatics , use OTC medication , exacerbation require hospitalisation last year , URTI within last six month , significant CVS inflammatory disease . IPF Use anti inflammatory med include statin , antihistamine , NSAIDs , salicylates , antirheumatics , use oral steroid 6 month , use antifibrotic therapy ( pirfendidone , nintedanib ) 6 month , FVC &lt; 50 % , baseline spO2 &lt; 90 % , use OTC medication , URTI within last 6 week , significant CVS disease . Sarcoidosis Same IPF , include use methotrexate 6 month . COPD Same asthma volunteer include atopy . TB Same IPF , include use antiTB drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>